Chinese Factory Antiviral Favipiravir Powder CAS 259793-96-9 Favipiravir

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A15
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Favipiravir
• Appearance: White Powder
• Assay: 99%
• CAS: 259793-96-9
• OEM: Available
• Sample: Available
• Suitable: Adult
• Function: Antiviral
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product  name	favipiravir
CAS	259793-96-9
Molecular  Formula	C5H4FN3O2
Molecular  weight	157.1
Apperance	White powder
purity	99%

Favipiravir, also known as T705, or Avigan, is a selective inhibitor of viral RNA-dependent RNA polymerase with activity against many RNA viruses, influenza viruses, West Nile virus,   foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Activity against enteroviruses   has also been demonstrated. The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase. Favipiravir does not inhibit RNA or DNA synthesis in mammalian cells and is not toxic to them.

1. Antiviral Treatment: Primarily used as a treatment option for certain viral infections, particularly in the context of influenza, where traditional antivirals may be less effective or unavailable.

2. Emergency Use Authorization (EUA): In various countries, it has been granted EUA for compassionate use or clinical trials in treating patients with severe viral infections, pending full approval.

3. Research Purposes: Widely studied in clinical trials and research settings to assess its efficacy, safety, and potential use in treating or preventing other viral diseases.

4. Pandemic Preparedness: Stockpiled by governments and healthcare organizations as part of pandemic preparedness strategies, given its broad-spectrum antiviral activity.

1. Inhibits Viral Replication: By targeting the RNA-dependent RNA polymerase (RdRp) enzyme, favipiravir interferes with the viral replication process, thereby limiting the spread of the virus within the host.

2. Broad-Spectrum Activity: Demonstrates antiviral activity against a wide range of RNA viruses, including influenza, Ebola, and, notably.

3. Mutagenic Effect: Its mechanism of action involves inducing mutations in the viral genome, leading to a decrease in the production of functional viral particles and eventual clearance of the infection.

4. Immune Modulation (Potential): Though not its primary function, some studies suggest that favipiravir may also have immunomodulatory effects, potentially enhancing the host's immune response against the virus.